Isabella Ciccone, MPH

Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.

The senior director of research strategy at Banner Alzheimer’s Institute talked about improving clinical trial diversity through removal of logistical barriers, creating inclusive outreach strategies, and designing trials that address the unique needs of underrepresented populations. [WATCH TIME: 5 minutes]

The director of the Banner Sun Health Research Institute talked about how the newly approved Alzheimer treatments have shown promise in slowing clinical decline, signaling a foundational shift toward disease-modifying therapies that target core biological processes. [WATCH TIME: 5 minutes]

The professor of molecular geriatrics at Uppsala University talked about the research journey that led to the development of targeted antibody therapies for Alzheimer disease and emphasized the need for early diagnosis. [WATCH TIME: 5 minutes]

The chair of psychiatry at Tufts University School of Medicine talked about a recent study that suggested synthetic tetrahydrocannabinol could reduce agitation in patients with advanced Alzheimer disease. [WATCH TIME: 5 minutes]

The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]

The head of dementia research at Austin Health and the chief medical officer at Cognition Therapeutics talked about recently presented phase 2 findings on CT1812, an investigational medicine for patients with mild to moderate Alzheimer disease, at CTAD 2024. [WATCH TIME: 5 minutes]

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation talked about how Alzheimer disease treatment may evolve through combination therapies, adding potential anti-tau and anti-inflammatory agents to improve patient outcomes. [WATCH TIME: 5 minutes]

The indication lead of neurology at Roche Diagnostics International talked about the latest Alzheimer biomarkers that are aimed to transform diagnostic accuracy and accessibility as well as enhance early detection and treatment. [WATCH TIME: 5 minutes]

A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]

The chief medical officer at Cognito Therapeutics talked about a medical device designed to slow cognitive decline in patients with Alzheimer disease through gamma frequency brain stimulation. [WATCH TIME: 6 minutes]

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.

Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Sana Aslam, DO, an assistant professor of neurology at University of Colorado School of Medicine.

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

Multiple sclerosis affects nearly 3 million patients worldwide; new research is helping pave the way for developing new therapies and medications that get at the defining mechanisms that trigger immune regulation loss of this unpredictable central nervous system disease.

In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.

The new guideline emphasized the importance of screening for risk factors and promoted healthy lifestyle changes to reduce the risk of stroke, which impacts over half a million patients in the United States.

The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital provided her immediate reaction to the approval of a once-nightly sodium oxybate for pediatric narcolepsy. [WATCH TIME: 7 minutes]

Neal K. Shah, chief executive officer at CareYaya Health Technologies, talked about Medicare making big moves in neurological care.

A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital talked about the new clinical guidelines for treating restless legs syndrome which emphasize the risks of dopamine agonists and advocate for alternative therapies. [WATCH TIME: 8 minutes]

A new analysis revealed zilucoplan’s long-term efficacy and safety in patients with generalized myasthenia gravis, with data extending to 120 weeks of treatment.

Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis.

Sodium oxybate is the only FDA-approved once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in pediatric patients with narcolepsy.

In clinical trials, patients with Parkinson disease who were treated with foscarbidopa/foslevodopa experienced superior improvement in ON time without dyskinesia compared with oral immediate-release carbidopa/levodopa.

Rozanolixizumab demonstrated efficacy in patients with generalized myasthenia gravis aged at least 65 years, despite a higher incidence of comorbidities observed in this population.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless legs syndrome.

A new analysis of the phase 3 PROPEL study showed that switching to cipaglucosidase alfa/miglustat therapy enhanced outcomes among patients with late-onset Pompe disease.

Using data from observational studies, a recent meta-analysis offered a comprehensive overview of the risk profile of cardiovascular comorbidities in patients with myasthenia gravis.